The World Health Organization reports that heart disease is the most common cause of death globally, accounting for 17.9 million fatalities annually. The fundamentals of a cure, it is thought, are important symptoms and recognition of the illness. Traditional techniques are facing many challenges, ranging from delayed or unnecessary treatment to incorrect diagnoses, which can affect treatment progress, increase the bill, and give the disease more time to spread and harm the patient's body. Such errors could be avoided and minimized by employing ML and AI techniques. Many significant efforts have been made in recent years to increase computer-aided diagnosis and detection applications, which is a rapidly growing area of research. Machine learning algorithms are especially important in CAD, which is used to detect patterns in medical data sources and make nontrivial predictions to assist doctors and clinicians in making timely decisions. This study aims to develop multiple methods for machine learning using the UCI set of data based on individuals' medical attributes to aid in the early detection of cardiovascular disease. Various machine learning techniques are used to evaluate and review the results of the UCI machine learning heart disease dataset. The proposed algorithms had the highest accuracy, with the random forest classifier achieving 96.72% and the extreme gradient boost achieving 95.08%. This will assist the doctor in taking appropriate actions. The proposed technology will only be able to determine whether or not a person has a heart issue. The severity of heart disease cannot be determined using this method.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931474PMC
http://dx.doi.org/10.1155/2023/9738123DOI Listing

Publication Analysis

Top Keywords

machine learning
20
heart disease
12
heart
5
machine
5
learning
5
disease
5
monitoring cardiovascular
4
cardiovascular problems
4
problems heart
4
heart patients
4

Similar Publications

Background: Developing drugs for treating Alzheimer's disease (AD) has been extremely challenging and costly due to limited knowledge on underlying biological mechanisms and therapeutic targets. Repurposing drugs or their combination has shown potential in accelerating drug development due to the reduced drug toxicity while targeting multiple pathologies.

Method: To address the challenge in AD drug development, we developed a multi-task machine learning pipeline to integrate a comprehensive knowledge graph on biological/pharmacological interactions and multi-level evidence on drug efficacy, to identify repurposable drugs and their combination candidates RESULT: Using the drug embedding from the heterogeneous graph representation model, we ranked drug candidates based on evidence from post-treatment transcriptomic patterns, mechanistic efficacy in preclinical models, population-based treatment effect, and Phase 2/3 clinical trials.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

AbbVie Inc., North Chicago, IL, USA.

Background: In Alzheimer's Disease (AD) trials, clinical scales are used to assess treatment effect in patients. Minimizing statistical uncertainty of trial outcomes is an important consideration to increase statistical power. Machine learning models can leverage baseline data to create AI-generated digital twins - individualized predictions (or prognostic scores) of how each patient's clinical outcomes may change during a trial assuming they received placebo.

View Article and Find Full Text PDF

Background: The prohibitive costs of drug development for Alzheimer's Disease (AD) emphasize the need for alternative in silico drug repositioning strategies. Graph learning algorithms, capable of learning intrinsic features from complex network structures, can leverage existing databases of biological interactions to improve predictions in drug efficacy. We developed a novel machine learning framework, the PreSiBOGNN, that integrates muti-modal information to predict cognitive improvement at the subject level for precision medicine in AD.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Imperial College London, London, United Kingdom; UK Dementia Research Institute, Care Research and Technology Centre, London, United Kingdom.

Background: Close to 23% of unplanned hospital admissions for people living with dementia (PLWD) are due to potentially preventable causes such as severe urinary tract infections (UTIs), falls, and respiratory problems. These affect the well-being of PLWD, cause stress to carers and increase pressure on healthcare services.

Method: We use routinely collected in-home sensory data to monitor nocturnal activity and sleep data.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Department of Psychology & Language Sciences, University College London, London, United Kingdom.

Background: Dysphagia is an important feature of neurodegenerative diseases and potentially life-threatening in primary progressive aphasia (PPA), but remains poorly characterised in these syndromes. We hypothesised that dysphagia would be more prevalent in nonfluent/agrammatic variant (nfv)PPA than other PPA syndromes, predicted by accompanying motor features and associated with atrophy affecting regions implicated in swallowing control.

Methods: In a retrospective case-control study at our tertiary referral centre, we recruited 56 patients with PPA (21 nfvPPA, 22 semantic variant (sv)PPA, 13 logopenic variant (lv)PPA).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!